Advanced

Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets

Chi, Kim N.; Bjartell, Anders LU ; Dearnaley, David; Saad, Fred; Schroeder, Fritz H.; Sternberg, Cora; Tombal, Bertrand and Visakorpi, Tapio (2009) In European Urology 56(4). p.594-605
Abstract
Context: Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. Objective: To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. Evidence acquisition: Novel targeted therapies in clinical trials were identified from registries. The MEDLINE database was searched for all relevant reports published from 1996 to October 2009. Bibliographies of the retrieved articles and major international meeting abstracts were hand-searched to identify additional studies. Evidence synthesis: Advances in our understanding of the molecular mechanisms underlying prostate cancer (PCa)... (More)
Context: Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. Objective: To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. Evidence acquisition: Novel targeted therapies in clinical trials were identified from registries. The MEDLINE database was searched for all relevant reports published from 1996 to October 2009. Bibliographies of the retrieved articles and major international meeting abstracts were hand-searched to identify additional studies. Evidence synthesis: Advances in our understanding of the molecular mechanisms underlying prostate cancer (PCa) progression has translated into a variety of treatment approaches. Agents targeting androgen receptor (AR) activation and local steroidogenesis, angiogenesis, immunotherapy, apoptosis, chaperone proteins, the insulin-like growth factor (IGF) pathway, RANK-ligand, endothelin receptors, and the Src family kinases are entering or have recently completed accrual to phase 3 trials for patients with CRPC. Conclusions: A number of new agents targeting mechanisms of PCa progression with early promising results are in clinical trials and have the potential to provide novel treatment options for CRPC in the near future. (C) 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Insulin-like growth factor-1, Clusterin, Chaperone proteins, Apoptosis, Immunotherapy, growth factor, Vascular endothelial, Androgen receptor, Prostate cancer, Androgens, Receptor activator of nuclear factor, kappa B, Endothelin, Src kinase
in
European Urology
volume
56
issue
4
pages
594 - 605
publisher
Elsevier
external identifiers
  • wos:000270071700004
  • scopus:69249203584
ISSN
1873-7560
DOI
10.1016/j.eururo.2009.06.027
language
English
LU publication?
yes
id
e4a3c972-4638-4069-934f-442a79697779 (old id 1490094)
date added to LUP
2009-10-20 11:14:04
date last changed
2017-12-10 04:11:32
@article{e4a3c972-4638-4069-934f-442a79697779,
  abstract     = {Context: Castration-resistant prostate cancer (CRPC) refers to patients who no longer respond to surgical or medical castration. Standard treatment options are limited. Objective: To review the concepts and rationale behind targeted agents currently in late-stage clinical testing for patients with CRPC. Evidence acquisition: Novel targeted therapies in clinical trials were identified from registries. The MEDLINE database was searched for all relevant reports published from 1996 to October 2009. Bibliographies of the retrieved articles and major international meeting abstracts were hand-searched to identify additional studies. Evidence synthesis: Advances in our understanding of the molecular mechanisms underlying prostate cancer (PCa) progression has translated into a variety of treatment approaches. Agents targeting androgen receptor (AR) activation and local steroidogenesis, angiogenesis, immunotherapy, apoptosis, chaperone proteins, the insulin-like growth factor (IGF) pathway, RANK-ligand, endothelin receptors, and the Src family kinases are entering or have recently completed accrual to phase 3 trials for patients with CRPC. Conclusions: A number of new agents targeting mechanisms of PCa progression with early promising results are in clinical trials and have the potential to provide novel treatment options for CRPC in the near future. (C) 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.},
  author       = {Chi, Kim N. and Bjartell, Anders and Dearnaley, David and Saad, Fred and Schroeder, Fritz H. and Sternberg, Cora and Tombal, Bertrand and Visakorpi, Tapio},
  issn         = {1873-7560},
  keyword      = {Insulin-like growth factor-1,Clusterin,Chaperone proteins,Apoptosis,Immunotherapy,growth factor,Vascular endothelial,Androgen receptor,Prostate cancer,Androgens,Receptor activator of nuclear factor,kappa B,Endothelin,Src kinase},
  language     = {eng},
  number       = {4},
  pages        = {594--605},
  publisher    = {Elsevier},
  series       = {European Urology},
  title        = {Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets},
  url          = {http://dx.doi.org/10.1016/j.eururo.2009.06.027},
  volume       = {56},
  year         = {2009},
}